All In Biotech

Drug Trial Radar · NCT07944690

A Phase I Study to Evaluate the Safety, Tolerability, and PK of HLX49 in Advanced/Metastatic Solid Tumors

A Phase I Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetics of HLX49 (Anti-HER2 Biparatopic and Bispecific ADC) in Participants With Advanced/Metastatic Solid Tumors

Last checked: Nov 20, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingRandomized with 222 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

222

Planned (sponsor's estimate)

Start

Nov 2026

Primary completion

Dec 2029

Study completion Dec 2030

Sponsor

Lead sponsor
Shanghai Henlius BiotechIndustry
Sponsor type
Industry
First posted
Nov 18, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is an open-label first-in-human phase I clinical study to evaluate the safety, tolerability, pharmacokinetic characteristics, and preliminary efficacy of HLX49 in patients with advanced/metastatic solid tumors.

Conditions

  • Advanced/Metastatic Solid Tumors

Interventions

  • HLX49Drug

    Patients with good tolerability and well controlled disease will receive the treatment once every 3 weeks (Q3W), until progressive disease (PD) without any clinical benefit, initiation of other anti-tumor therapies, death, intolerable toxicity, or withdraw the informed consent (whichever occurs first).

  • Trastuzumab Deruxtecan for Injection (T-DXd)Drug

    Patients with good tolerability and well controlled disease will receive Trastuzumab deruxtecan via intravenous infusion once every 3 weeks (Q3W), until progressive disease (PD) without any clinical benefit, initiation of other anti-tumor therapies, death, intolerable toxicity, or withdraw the informed consent (whichever occurs first).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The Dose-Limiting Toxicity (DLT) of HLX49 within 21 days after the first AdministrationTime frame: From first dose to the end of Cycle 1 (each cycle is 3 weeks).
  2. The maximum tolerated dose (MTD) of HLX49Time frame: From first dose to the end of Cycle 1 (each cycle is 3 weeks).
  3. RP2DTime frame: Approximately up to 24 months.
  4. Objective response rate (ORR) assessed by IRRCTime frame: Approximately up to 24 months.

Locations

2 sites in 2 countries. Site status is shown where the registry gives one.

  • Sunshine Coast University Hospital

    Sunshine Coast, Australia

  • Beijing Cancer Hospital

    Beijing, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.